SECURITIES AND FUTURES ACT (CAP. 289)
SECURITIES AND FUTURES (DISCLOSURE OF INTERESTS) REGULATIONS 2012

NOTIFICATION FORM FOR DIRECTOR/CHIEF EXECUTIVE OFFICER IN RESPECT OF INTERESTS IN SECURITIES

FORM **1** (Electronic Format)

Explanatory Notes

1. Please read the explanatory notes carefully before completing this notification form.
2. This form is for a Director/Chief Executive Officer ("CEO") to give notice of his interests in the securities of the Listed Issuer under section 133, 137N or 137Y of the Securities and Futures Act (Cap. 289) (the "SFA"). Please note that the requirement to disclose interests in participatory interests applies **only** to a director and where the Listed Issuer is a Singapore-incorporated company.
3. This electronic Form 1 and a separate Form C, containing the particulars and contact details of the Director/CEO, must be completed by the Director/CEO or a person duly authorised by him to do so. The person so authorised should maintain records of information furnished to him by the Director/CEO.
4. This form and Form C, are to be completed electronically and sent to the Listed Issuer via an electronic medium such as an e-mail attachment. The Listed Issuer will attach both forms to the prescribed SGXNet announcement template for dissemination as required under section 137G(1), 137R(1) or 137ZC(1) of the SFA, as the case may be. While Form C will be attached to the announcement template, it will not be disseminated to the public and is made available only to the Monetary Authority of Singapore (the "Authority").
5. A single form may be used by a Director/CEO for more than one transaction resulting in notifiable obligations which occur within the same notifiable period (i.e. within two business days of/of becoming aware of, the earliest transaction). There must be no netting-off of two or more notifiable transactions even if they occur within the same day.
6. All applicable parts of the notification form must be completed. If there is insufficient space for your answers, please include attachment(s) by clicking on the paper clip icon on the bottom left-hand corner or in item 3 of Part II or item 10 of Part III. The total file size for all attachment(s) should not exceed 1MB.
7. Except for item 4 of Part III, please select only one option from the relevant check boxes.
8. Please note that submission of any false or misleading information is an offence under Part VII of the SFA.
9. In this form, the term "Listed Issuer" refers to –
   (a) a company incorporated in Singapore any or all of the shares in which are listed for quotation on the official list of a securities exchange;
   (b) a corporation (not being a company incorporated in Singapore, or a collective investment scheme constituted as a corporation) any or all of the shares in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing;
   (c) a registered business trust (as defined in the Business Trusts Act (Cap. 31A)) any or all of the units in which are listed for quotation on the official list of a securities exchange;
   (d) a recognised business trust any or all of the units in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing; or
   (e) a collective investment scheme that is a trust, that invests primarily in real estate and real estate-related assets specified by the Authority in the Code on Collective Investment Schemes, and any or all the units in which are listed for quotation on the official list of a securities exchange, such listing being a primary listing ("Real Estate Investment Trust").
10. For further instructions and guidance on how to complete this notification form, please refer to section 6 of the User Guide on Electronic Notification Forms which can be accessed at the Authority's Internet website at http://www.mas.gov.sg (under "Regulations and Financial Stability", "Regulations, Guidance and Licensing", "Securities, Futures and Fund Management", "Forms", "Disclosure of Interests").

Export XML

Part I - General

1. Name of Listed Issuer:

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

2. Type of Listed Issuer:

- [x] Company/Corporation
- [ ] Registered/Recognised Business Trust
- [ ] Real Estate Investment Trust

3. Name of Director/CEO:

Guo Min

4. Is the Director/CEO also a substantial shareholder/unitholder of the Listed Issuer?

- [x] Yes
- [ ] No

5. Is the Director/CEO notifying in respect of his interests in securities of, or made available by, the Listed Issuer at the time of his appointment?

- [ ] Yes *(Please proceed to complete Part II)*
- [x] No *(Please proceed to complete Part III)*

6. Date of notification to Listed Issuer:

05-Feb-2026

Part III - For an incumbent Director/CEO giving notice of an acquisition of, or a change in his interest in, securities of or made available by the Listed Issuer

Transaction A

1. Date of acquisition of or change in interest:

   04-Feb-2026

2. Date on which Director/CEO became aware of the acquisition of, or change in, interest (*if different from item 1 above, please specify the date*):

   04-Feb-2026

3. Explanation (*if the date of becoming aware is different from the date of acquisition of, or change in, interest*):

   N.A.

4. Type of securities which are the subject of the transaction *(more than one option may be chosen):*

   - [x] Ordinary voting shares/units of Listed Issuer
   - [ ] Other types of shares/units (*excluding ordinary voting shares/units*) of Listed Issuer
   - [ ] Rights/Options/Warrants over shares/units of Listed Issuer
   - [ ] Debentures of Listed Issuer
   - [ ] Rights/Options over debentures of Listed Issuer
   - [ ] Contracts over shares of the Listed Issuer which Director/CEO is a party to, or under which he is entitled to a benefit, being contracts under which any person has a right to call for or to make delivery of shares in the Listed Issuer
   - [ ] Participatory interests made available by Listed Issuer
   - [ ] Others (*please specify*):

5. Number of shares, units, rights, options, warrants, participatory interests and/or principal amount/value of debentures or contracts acquired or disposed of by Director/CEO:

   N.A. Please refer to Item 9 below.

6. Amount of consideration paid or received by Director/CEO (*excluding brokerage and stamp duties*):

   N.A. Please refer to Item 9 below.

7. Circumstance giving rise to the interest or change in interest:

Acquisition of:

- ☐ Securities via market transaction
- ☐ Securities via off-market transaction (*e.g. married deals*)
- ☐ Securities via physical settlement of derivatives or other securities
- ☐ Securities pursuant to rights issue
- ☐ Securities via a placement
- ☐ Securities following conversion/exercise of rights, options, warrants or other convertibles

Disposal of:

- ☐ Securities via market transaction
- ☐ Securities via off-market transaction (*e.g. married deals*)

Other circumstances :

- ☐ Acceptance of employee share options/share awards
- ☐ Vesting of share awards
- ☐ Exercise of employee share options
- ☐ Acceptance of take-over offer for Listed Issuer
- ☐ Corporate action by Listed Issuer (*please specify*):

- ☑ Others (*please specify*):

Please refer to Item 9 below.

8. Quantum of interests in securities held by Director/CEO before and after the transaction. Please complete relevant table(s) below (*for example, Table 1 should be completed if the change relates to ordinary voting shares of the Listed Issuer; Table 4 should be completed if the change relates to debentures*):

Table 1. Change in respect of **ordinary voting shares/units** of Listed Issuer

Immediately before the transaction	*Direct Interest*	*Deemed Interest*	*Total*
No. of ordinary voting shares/units held:	0	331,120,528	331,120,528
As a percentage of total no. of ordinary voting shares/units:	0	42.997	42.997
Immediately after the transaction	*Direct Interest*	*Deemed Interest*	*Total*
No. of ordinary voting shares/units held:	0	331,202,728	331,202,728

As a percentage of total no. of ordinary voting shares/units:	0	43.008	43.008

9. Circumstances giving rise to deemed interests (*if the interest is such*):
[You may attach a chart(s) in item 10 to illustrate how the Director/CEO's deemed interest, as set out in item 8 tables 1 to 8, arises]

JinYao Global Pte. Ltd. (formerly known as Tianjin Pharmaceutical (Singapore) International Investment Pte. Ltd.) ("JinYao Global") had, on 4 February 2026, acquired 82,200 S-Shares (being ordinary shares issued by Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (the "Company") to natural and legal persons in countries other than People's Republic of China, denominated in United States dollars and listed on the Singapore Exchange Securities Trading Limited (the "SGX-ST")) through the trading system of the SGX-ST at an average price of approximately US$2.96 per S-Share, for an aggregate consideration of approximately US$242,952.79.

As JinYao Global is a wholly-owned subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd. ("TPH") as at the date of this notification, pursuant to Section 4 of the Securities and Futures Act 2001 of Singapore (the "SFA"), TPH is deemed to have an interest in the ordinary shares (the "Shares") in the capital of the Company in which JinYao Global has an interest.

As at the date of this notification:

(a) TPH is 67% held by Jinhushen Biological Medical Science and Technology Co., Ltd. ("Jinhushen");

(b) the shareholders of Jinhushen comprising (i) Shanghai Liuliguang Medical Development Co., Ltd. ("Liuliguang Medical"); (ii) Shenzhen Qianhai Furong Asset Management Co., Ltd. ("Qianhai Furong"); (iii) Shenzhen Ruice Biological Medical Development Co., Ltd.; and (iv) Hainan Special Economic Zone Yousheng Enterprise Management Limited Partnership, which respectively hold 35%, 34%, 16% and 15% of the equity interests in Jinhushen;

(c) Shanghai Industrial Investment (holdings) Co., Ltd. ("SIIC") has a 51% equity interest in Liuliguang Medical; and

(d) Qianhai Furong is a wholly-owned subsidiary of Shenzhen Yierde Investment Co., Ltd. ("Shenzhen Yierde"), which is in turn 99.999% held by Mr. Guo Min.

Accordingly, each of Jinhushen, Liuliguang Medical, SIIC, Qianhai Furong, Shenzhen Yierde, and Mr. Guo Min is deemed to have an interest in the Shares in which TPH has, or is deemed to have, an interest.

10. Attachments (*if any*):

(The total file size for all attachment(s) should not exceed 1MB.)

11. If this is a **replacement** of an earlier notification, please provide:

(a) SGXNet announcement reference of the **first** notification which was announced on SGXNet (*the "Initial Announcement"*):

(b) Date of the Initial Announcement:

(c) 15-digit transaction reference number of the relevant transaction in the Form 1 which was attached in the Initial Announcement:

12. Remarks (*if any*):

Transaction Reference Number (*auto-generated*):

4	2	3	8	9	2	9	4	5	4	4	6	4	0	9

Item 13 is to be completed by an individual submitting this notification form on behalf of the Director/CEO.

13. Particulars of Individual submitting this notification form to the Listed Issuer:

(a) Name of Individual:

Liang Linlin

(b) Designation (*if applicable*):

Investment Manager of the Investment and Development Department

(c) Name of entity (*if applicable*):

Tianjin Pharmaceutical Holdings Co., Ltd.